Stocks That Hit 52-Week Lows On Thursday
Thursday's morning session saw 8 companies set new 52-week lows.
Medicenna Announces Submission Of Clinical Trial Application In Australia For Phase 1/2 Study Of MDNA11
Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced that it has submitted a clinical trial application to a
HC Wainwright & Co. Maintains Buy on Medicenna Therapeutics, Lowers Price Target to $7
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Medicenna Therapeutics (NASDAQ:MDNA) with a Buy and lowers the price target from $8 to $7.
Earnings Scheduled For May 28, 2021
Companies Reporting Before The Bell
• MOGU (NYSE:MOGU) is expected to report earnings for its fourth quarter.
MDNA: Targeting ‘Cold’ Tumors with Dual Cytokine
By David Bautz, PhD
NASDAQ:MDNA
READ THE FULL MDNA RESEARCH REPORT